Treatment of neurodegenerative disease with sodium chlorite
AssigneesNeuvivo, Inc., The Regents of the University of California
InventorsVernon A. Norviel, Michael S. McGrath
Life of this patent
Estimating the term…
Abstract
The present invention provides a method of treating frontotemporal dementia, or a childhood genetic neurodegenerative disease such as Ataxia Telangiectasia (A-T), or neurodegenerative diseases such as Parkinson's disease or neuropsychiatric diseases comprising administering to a subject in need thereof an effective amount of chlorite composition, such as sodium chlorite. The present invention thereby provides a method of modulating the immune system in a subject in need thereof. Described herein are methods of administration and treatment.
Claims20
A method of treating Amyotrophic Lateral Sclerosis (ALS) in a subject in need thereof, the method comprising:
- a) determining that the subject has a plasma level of C-reactive protein that is at least 1125 ng/ml;
- and
- b) based on the determining that the subject has the plasma level of C-reactive protein that is at least 1125 ng/mL, administering to the subject an amount of sodium chlorite that is therapeutically-effective for Amyotrophic Lateral Sclerosis (ALS),
- wherein the subject is human;
- wherein the subject exhibits a symptom of Amyotrophic Lateral Sclerosis (ALS);
- wherein the sodium chlorite is administered in an amount ranging from 0.1 to 10 mg/kg by body weight of the subject;
- wherein the administering occurs at least once per month for a period of at least a year;
- and
- wherein the administering occurs over a period ranging from about 0.5 to about 4 hours.
A method of treating Amyotrophic Lateral Sclerosis (ALS) in a subject in need thereof, the method comprising:
- a) determining that the subject has a plasma level of C-reactive protein that is at least 1125 ng/ml;
- and
- b) based on the determining that the subject has the plasma level of C-reactive protein that is at least 1125 ng/mL, administering to the subject an amount of sodium chlorite that is therapeutically-effective for Amyotrophic Lateral Sclerosis (ALS),
- wherein the subject is human;
- wherein the subject exhibits a behavioral symptom of Amyotrophic Lateral Sclerosis (ALS);
- wherein the subject exhibits a physical symptom of Amyotrophic Lateral Sclerosis (ALS);
- wherein the sodium chlorite is administered in an amount ranging from 1 to 2 mg/kg by body weight of the subject;
- wherein the administering occurs at least once per month for a period of at least a year;
- wherein the administering occurs over a period ranging from about 0.5 to about 4 hours;
- wherein the administering is parenteral;
- wherein the administering of the sodium chlorite is by administration of a formulation,
- wherein the formulation comprises:
- a) the sodium chlorite;
- b) phosphate buffer;
- c) chloride ions in an amount of less than about 1% of chlorite ions in the formulation;
- and
- d) chlorate ions in an amount of less than about 1.5% of chlorite ions in the formulation,
- wherein the formulation has a pH of about 7 to about 11.
A method of treating Amyotrophic Lateral Sclerosis (ALS) in a subject in need thereof, the method comprising:
- a) determining that the subject has a plasma level of C-reactive protein that is at least 1125 ng/ml;
- and
- b) based on the determining that the subject has the plasma level of C-reactive protein that is at least 1125 ng/mL, administering to the subject an amount of sodium chlorite that is therapeutically-effective for Amyotrophic Lateral Sclerosis (ALS),
- wherein the subject is human;
- wherein the subject exhibits a speech disorder;
- wherein the subject exhibits poor coordination;
- wherein the subject exhibits progressive muscle weakness;
- wherein the subject exhibits progressive muscle wasting;
- wherein the subject exhibits respiratory failure;
- wherein the sodium chlorite is administered in an amount ranging from 1 to 2 mg/kg by body weight of the subject;
- wherein the administering occurs at least once per month for a period of at least a year;
- wherein the administering occurs over a period ranging from about 0.5 to about 4 hours;
- wherein the administering is intravenous;
- wherein the administration of the sodium chlorite is by administration of a formulation,
- wherein the formulation comprises:
- a) the sodium chlorite;
- b) phosphate buffer;
- c) chloride ions in an amount from about 0.1% to about 0.5% of chlorite ions in the formulation;
- and
- d) chlorate ions in an amount from about 0.1% to about 0.5% of chlorite ions in the formulation,
- wherein the formulation has a pH of about 7 to about 9.5.
Dependencies are inferred from the claim text.